Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of XW003 on PK of Metformin, Warfarin, Rosuvastatin or Digoxin
NCT06335134Phase 1Completed
- Sponsor
- Sciwind Biosciences
- Start
- Jul 2023
- Primary completion
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of ecnoglutide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Sciwind Biosciences. Primary endpoints: Area under the concentration-time curve from time zero to infinity for metformin up to 101 days, Area under the concentration-time curve from time zero to infinity for S-warfarin and R-warfarin up to 114 days and 2 more. Started Jul 2023; status: completed.
02
Drugs
ecnoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06335134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335134.